undamentalytics Newsletter
Sign in

Bruker Corp (BRKR) stock

Add to watchlist

Add holding +

NASDAQ: BRKR Nasdaq Life Sciences Tools & Services Next results ~November 4, 2026

C+ Fundamentals grade

Bruker Corp is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: our cash-flow value ($4.39) was left out of our combined valuation (it is 0.07x the share price, outside the 0.2-5x range we accept), so it can't be the basis of a rating.

Price vs value

Under review: our cash-flow value ($4.39) was left out of our combined valuation (it is 0.07x the share price, outside the 0.2-5x range we accept), so it can't be the basis of a rating. We'll show the comparison once resolved.

Bruker Corp valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 4 selling0 purchases and 16 sales by directors and officers, last 12 monthsInsider trades
  • Funds238 adding, 162 cuttingOf 61 active managers that changed their stake, 37 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Bruker files

Where Bruker stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $3.50bn, up 1.6% on a year earlier, faster than 0.4% a quarter earlier. That puts it 777 of 931 for growth among all the companies we cover. Free-cash-flow margin rose to 2.7% from 1.4% a year earlier. Operating margin narrowed to -0.9% from 5.3%. The diluted share count is down 2.0% on a year earlier, which lifts each remaining share. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 2 of our 6 financial-health checks.

Our model value for Bruker is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Bruker Corp's trailing-twelve-month revenue grew 1.6% year on year, with a free-cash-flow margin of 2.7%. Where it stands out: stock pay as % of revenue of 0.6% ranks 2 of 53 life sciences tools & services companies we cover.

Our discounted-cash-flow model values the business at ~$4.4 per share in the base case (~$0.4–$9.6 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 28% in the quarter to 2026-06-30, the 3rd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Shrinking share count. Diluted shares fell 2.0% in a year, so each share owns more of the business.

Things to watch

  • Loss-making. Operating margin is -0.9%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 6.2 points on a year ago.
  • Volatile shares. Over the past year the shares showed annualised volatility of 56% and a beta of 1.5 against the S&P 500.
  • Heavily shorted. 16.0% of the shares available to trade are sold short (5.3 days of average volume to cover).

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
$0.49 against an average estimate of $0.38: beat by 27.5%
Revenue
$839m, up 5.2% on a year earlier
Share reaction
-18.4% in the first session after the results on August 4, 2026, against +1.6% for the S&P 500
Guidance given
FY26 revenues $3.54bn to $3.57bn (FY26); reported revenue growth growth 3% to 4% (FY26)
Next report
November 4, 2026; average EPS estimate $0.42

Bruker's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-2.4%
  • 1 week-4.4%
  • 1 month-11.9%
  • This year+18.6%
  • 1 year+43.6%
  • 5 years-30.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$3.5B
Operating margin
-0.9%
Net margin
-2.0%
EPS (TTM, diluted)
$-0.47

Growth

Revenue growth
+1.6%
Change in growth rate
+1.3 pts

Cash

Free cash flow (TTM)
$93.9M
FCF margin
2.7%
Stock pay % of revenue
0.6%

Earnings

Last results
August 4, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Announcement
  4. Announcement
  5. Announcement
  6. Announcement
  7. Announcement
  8. Announcement
  9. Results
  10. Guidance
  11. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Bruker Corp valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: held for review: our cash-flow value ($4.39) was left out of our combined valuation (it is 0.07x the share price, outside the 0.2-5x range we accept), so it can't be the basis of a rating.

Our value per share comes from a discounted-cash-flow model of Bruker Corp's free cash flow after stock-based pay ( $123M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Bruker Corp as an operating company, with every model that fits that kind of business. Cost of equity 9.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.03 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$4.4 ~$0.4–$9.6 Left out: out of range vs price (0.08x)
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$56 ~$43–$77 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$32 ~$23–$45 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$31 ~$27–$36 Included
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Bruker Corp with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$23.23$20.41$33.25$28.99$49.82$53.09$82.48$67.40$72.67$58.14$46.96$55.69
Market value$3.9bn$3.3bn$5.3bn$4.6bn$7.8bn$8.2bn$12.6bn$10.1bn$10.7bn$8.7bn$7.1bn$8.5bn
+ Net debt (− = net cash)−$1m$69m$91m$19m$135m$163m$266m$574m$793m$1.9bn$1.6bn$1.6bn
Enterprise value$3.9bn$3.4bn$5.4bn$4.6bn$7.9bn$8.4bn$12.9bn$10.6bn$11.5bn$10.6bn$8.7bn$10.1bn
Multiples
Price / sales 2.4x2.1x3.0x2.4x3.8x4.1x5.2x4.0x3.6x2.6x2.1x2.4x
Price / earnings 38.7x21.5x67.3x25.4x39.6x52.0x45.5x33.9x25.0x76.9x——
Price / free cash flow 20.1x35.3x47.8x23.9x55.6x34.9x66.2x69.3x44.0x63.9x164.6x90.2x
EV / EBITDA 19.7x14.3x19.0x14.0x21.1x25.5x25.6x20.4x20.8x24.3x30.2x50.7x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

66 /100

Moderate moat

How hard Bruker's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 20 / 20

    Cash operating profit has been a median 15.2% of total assets over 10 years.

  • Pricing power 16 / 20

    Gross margin has been a median 48.0%, moving by 1.8 percentage points (standard deviation) across 10 years.

  • Durability 3 / 20

    Operating margin has been a median 12.9%; its worst year was -0.9%.

  • Cash conversion 13 / 20

    Free cash flow was positive in 10 of 10 years, at a median 6.2% of revenue.

  • Discipline 18 / 20

    The diluted share count fell 5.3% over five years; stock-based pay has been a median 0.7% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (71 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, before the open. Analysts expect revenue of $865m and EPS of $0.42 (range $0.39 to $0.45) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $2.12 +16% $3.6bn +4%
Next $2.40 +13% $3.7bn +4%

Next year's EPS estimate has moved −1.1% in 90 days, across 13 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +0.0% on 90 days ago. In the last 30 days, 0 analysts raised Bruker Corp's forecast and 2 cut it.

Consensus EPS forecast Bruker Corp, last 90 days
$2.10 $2.20 $2.30 $2.40 $2.50 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $2.12 Current fiscal year, 60 days ago: $2.12 Current fiscal year, 30 days ago: $2.12 Current fiscal year, 7 days ago: $2.12 Current fiscal year, Now: $2.12 $2.12 Next fiscal year, 90 days ago: $2.43 Next fiscal year, 60 days ago: $2.41 Next fiscal year, 30 days ago: $2.39 Next fiscal year, 7 days ago: $2.40 Next fiscal year, Now: $2.40 $2.40

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $2.12$2.43
60 days ago $2.12$2.41
30 days ago $2.12$2.39
7 days ago $2.12$2.40
Now $2.12$2.40

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.38 $0.49 +27.5%
Mar 2026 $0.23 $0.31 +34.8%
Dec 2025 $0.65 $0.59 −9.8%
Sept 2025 $0.32 $0.45 +38.8%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 4, 2026
  • FY26 revenues FY26 $3.54bn to $3.57bn
    “Bruker now expects FY26 revenues of $3.54 to $3.57 billion, compared to FY25 revenues of $3.44 billion, with 3% to 4% year-over-year reported revenue growth, including:” source
  • reported revenue growth FY26 3% growth to 4% growth
    “Bruker now expects FY26 revenues of $3.54 to $3.57 billion, compared to FY25 revenues of $3.44 billion, with 3% to 4% year-over-year reported revenue growth, including:” source
  • Organic revenue growth FY26 1% growth to 2% growth Non-GAAP
    “Organic revenue growth of 1% to 2%” source
  • M&A revenue growth FY26 about 1.5% growth Non-GAAP
    “M&A revenue growth of approximately 1.5%,” source
  • CER revenue growth FY26 2.5% growth to 3.5% growth Non-GAAP
    “CER revenue growth of 2.5% to 3.5%, and” source
  • Foreign currency translation revenue tailwind FY26 about 0.5% growth Lowered
    “Foreign currency translation revenue tailwind of approximately 0.5% (previously 1.5%).” source
Show 3 more items
  • non-GAAP EPS FY26 $2.10 to $2.15 Non-GAAP Maintained
    “Bruker continues to expect FY26 non-GAAP EPS of $2.10 to $2.15 compared to $1.83 in FY25, an increase of 15% to 17% year-over-year, now at an effective non-GAAP tax rate of 27.5%.” source
  • non-GAAP EPS year-over-year increase FY26 15% growth to 17% growth Non-GAAP Maintained
    “Bruker continues to expect FY26 non-GAAP EPS of $2.10 to $2.15 compared to $1.83 in FY25, an increase of 15% to 17% year-over-year, now at an effective non-GAAP tax rate of 27.5%.” source
  • effective non-GAAP tax rate FY26 about 27.5% Non-GAAP
    “Bruker continues to expect FY26 non-GAAP EPS of $2.10 to $2.15 compared to $1.83 in FY25, an increase of 15% to 17% year-over-year, now at an effective non-GAAP tax rate of 27.5%.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

How our valuation uses these forecasts

Our cash-flow model grows Bruker Corp's revenue by +4.1% next year and +4.9% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+3.8%, weight 55%) , management guidance (+3.7%, weight 19%) and the company's own record (+5.2%, weight 26%) . How the weights are set.

Analyst recommendations

13 analysts, Oct 2026
Buy646%
Hold646%
Sell18%

Monthly trend

  1. Oct 2026156113
  2. Sep 2026255113
  3. Aug 2026264113
  4. Jul 2026264113

Counts of recommendations published by analysts covering Bruker Corp, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
16.0%
of tradable shares
Days to cover
5.27
at average volume
Short interest, 1 month
+1%
to October 15, 2026
Held by institutions
95%
of shares
Held by insiders
27.0%
of shares
Employees
11,085
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +43.6%

$38.78 on October 31, 2025 to $55.69

ThenNowEffect
Revenue (last 12 months) $3.4bn $3.5bn +1.6%
P/S multiple 1.7x 2.4x +42.5%
Share count 151m 152m −0.8%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −4.2%

$58.13 on November 3, 2023 to $55.69

ThenNowEffect
Revenue (last 12 months) $2.7bn $3.5bn +28.9%
P/S multiple 3.2x 2.4x −23.6%
Share count 148m 152m −2.8%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
BRKR+55%−18%+8%−20%−19%+19%
Industry peers (median)+4%−53%−3%−13%−2%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
BRKR92%58%50%50%25%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
BRKR−18%−42%−35%−49%−53%−40%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 69% from March 21, 2024 to September 3, 2025. Getting back needed a 220% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$32.66 – $64.75
From 52-week high
−14.0%
vs 50-day average
−5.3%
vs 200-day average
+11.0%
Volatility (1 year)
57%
Beta vs S&P 500
1.47

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±7.5%
After a week
3 up, 9 down
typical move ±8.1%
After a month
3 up, 9 down
typical move ±15.9%
Results releasedNext dayS&P 500 next day5 days21 days
August 4, 2026 −18.4% +1.6% −11.3% −8.2%
May 6, 2026 +15.0% +1.1% +15.4% +48.4%
February 12, 2026 −14.0% −1.5% −9.8% −22.8%
January 12, 2026 −6.6% 0.0% −8.5% −22.1%
November 3, 2025 +3.7% −1.0% +4.7% +22.9%
August 4, 2025 −15.6% +1.0% −19.0% −22.7%
July 21, 2025 −4.3% +0.2% +8.3% −14.1%
May 7, 2025 +2.7% +1.1% −6.6% −2.9%
April 11, 2025 +5.0% +2.8% −5.5% +1.8%
February 13, 2025 −3.1% +1.1% −1.6% −9.0%
January 13, 2025 +0.8% +0.3% −1.2% −15.0%
November 5, 2024 −0.6% +3.7% −5.6% −1.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Bruker Corp in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Bruker Corp
$2.8B $3B $3.2B $3.4B $3.6B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $2.8B Revenue (TTM), FY23 Q4: $3B Revenue (TTM), FY24 Q1: $3B Revenue (TTM), FY24 Q2: $3.1B Revenue (TTM), FY24 Q3: $3.2B Revenue (TTM), FY24 Q4: $3.4B Revenue (TTM), FY25 Q1: $3.4B Revenue (TTM), FY25 Q2: $3.4B Revenue (TTM), FY25 Q3: $3.4B Revenue (TTM), FY25 Q4: $3.4B Revenue (TTM), FY26 Q1: $3.5B Revenue (TTM), FY26 Q2: $3.5B $3.5B

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $2.8B
FY23 Q4 $3B
FY24 Q1 $3B
FY24 Q2 $3.1B
FY24 Q3 $3.2B
FY24 Q4 $3.4B
FY25 Q1 $3.4B
FY25 Q2 $3.4B
FY25 Q3 $3.4B
FY25 Q4 $3.4B
FY26 Q1 $3.5B
FY26 Q2 $3.5B
Revenue growth, TTM YoY Bruker Corp
0% 5% 10% 15% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 12.5% Revenue growth, TTM YoY, FY23 Q4: 17.1% Revenue growth, TTM YoY, FY24 Q1: 14.5% Revenue growth, TTM YoY, FY24 Q2: 14.9% Revenue growth, TTM YoY, FY24 Q3: 15.0% Revenue growth, TTM YoY, FY24 Q4: 13.6% Revenue growth, TTM YoY, FY25 Q1: 14.8% Revenue growth, TTM YoY, FY25 Q2: 10.4% Revenue growth, TTM YoY, FY25 Q3: 6.1% Revenue growth, TTM YoY, FY25 Q4: 2.1% Revenue growth, TTM YoY, FY26 Q1: 0.4% Revenue growth, TTM YoY, FY26 Q2: 1.6% 1.6%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 12.5%
FY23 Q4 17.1%
FY24 Q1 14.5%
FY24 Q2 14.9%
FY24 Q3 15.0%
FY24 Q4 13.6%
FY25 Q1 14.8%
FY25 Q2 10.4%
FY25 Q3 6.1%
FY25 Q4 2.1%
FY26 Q1 0.4%
FY26 Q2 1.6%
Operating margin (TTM) Bruker Corp
-5% 0% 5% 10% 15% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 16.5% Operating margin (TTM), FY23 Q4: 14.7% Operating margin (TTM), FY24 Q1: 12.6% Operating margin (TTM), FY24 Q2: 10.9% Operating margin (TTM), FY24 Q3: 8.8% Operating margin (TTM), FY24 Q4: 7.5% Operating margin (TTM), FY25 Q1: 6.4% Operating margin (TTM), FY25 Q2: 5.3% Operating margin (TTM), FY25 Q3: 1.9% Operating margin (TTM), FY25 Q4: 2.0% Operating margin (TTM), FY26 Q1: 1.3% Operating margin (TTM), FY26 Q2: -0.9% -0.9%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 16.5%
FY23 Q4 14.7%
FY24 Q1 12.6%
FY24 Q2 10.9%
FY24 Q3 8.8%
FY24 Q4 7.5%
FY25 Q1 6.4%
FY25 Q2 5.3%
FY25 Q3 1.9%
FY25 Q4 2.0%
FY26 Q1 1.3%
FY26 Q2 -0.9%
FCF margin (TTM) Bruker Corp
-5% 0% 5% 10% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 7.3% FCF margin (TTM), FY23 Q4: 8.2% FCF margin (TTM), FY24 Q1: 6.0% FCF margin (TTM), FY24 Q2: 5.4% FCF margin (TTM), FY24 Q3: 4.8% FCF margin (TTM), FY24 Q4: 4.0% FCF margin (TTM), FY25 Q1: 5.1% FCF margin (TTM), FY25 Q2: 1.4% FCF margin (TTM), FY25 Q3: -0.3% FCF margin (TTM), FY25 Q4: 1.3% FCF margin (TTM), FY26 Q1: 1.5% FCF margin (TTM), FY26 Q2: 2.7% 2.7%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 7.3%
FY23 Q4 8.2%
FY24 Q1 6.0%
FY24 Q2 5.4%
FY24 Q3 4.8%
FY24 Q4 4.0%
FY25 Q1 5.1%
FY25 Q2 1.4%
FY25 Q3 -0.3%
FY25 Q4 1.3%
FY26 Q1 1.5%
FY26 Q2 2.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 1,115 1,305 1,652 1,791 1,839 1,809 1,624 1,611 1,766 1,896 2,073 1,988 2,418 2,531 2,965 3,366 3,437 3,500
Gross profit 518 604 753 829 805 763 709 745 816 900 995 940 1,210 1,306 1,513 1,650 1,578 1,624
EBITDA 166 192 209 215 210 165 199 236 283 327 377 329 502 522 552 437 289 200
Operating income 137 156 156 156 148 105 146 182 220 262 301 248 413 433 437 253 68 −31
Net income 81 95 92 78 80 57 102 154 79 180 197 158 277 297 427 113 −9 −71
Diluted EPS $0.49 $0.58 $0.55 $0.46 $0.48 $0.33 $0.60 $0.95 $0.49 $1.14 $1.26 $1.02 $1.81 $1.99 $2.90 $0.76 −$0.15 −$0.47
Growth (year on year)
Revenue — +17.1% +26.6% +8.5% +2.7% −1.7% −10.2% −0.8% +9.6% +7.3% +9.3% −4.1% +21.7% +4.7% +17.1% +13.6% +2.1% +1.6%
EBITDA — +15.3% +8.7% +3.2% −2.6% −21.2% +20.5% +18.6% +20.0% +15.5% +15.0% −12.7% +52.8% +3.8% +5.8% −20.8% −34.0% −49.4%
Operating income — +13.9% −0.1% +0.3% −5.0% −28.9% +38.2% +24.8% +20.7% +19.5% +14.7% −17.5% +66.5% +4.7% +1.0% −42.1% −73.1% −116.6%
Net income — +17.5% −3.2% −16.0% +3.4% −29.2% +79.2% +51.2% −48.8% +128.6% +9.7% −20.0% +75.6% +7.0% +44.0% −73.5% −107.6% −189.4%
Diluted EPS — +18.4% −5.2% −16.4% +4.3% −31.3% +81.8% +58.3% −48.4% +132.7% +10.5% −19.0% +77.5% +9.9% +45.7% −73.8% −119.7% —
Margins
Gross margin 46.4% 46.3% 45.6% 46.3% 43.8% 42.2% 43.6% 46.3% 46.2% 47.5% 48.0% 47.3% 50.0% 51.6% 51.0% 49.0% 45.9% 46.4%
EBITDA margin 14.9% 14.7% 12.6% 12.0% 11.4% 9.1% 12.3% 14.7% 16.0% 17.3% 18.2% 16.5% 20.8% 20.6% 18.6% 13.0% 8.4% 5.7%
Operating margin 12.3% 11.9% 9.4% 8.7% 8.1% 5.8% 9.0% 11.3% 12.4% 13.8% 14.5% 12.5% 17.1% 17.1% 14.7% 7.5% 2.0% −0.9%
Net margin 7.3% 7.3% 5.6% 4.3% 4.4% 3.1% 6.3% 9.5% 4.5% 9.5% 9.5% 7.9% 11.5% 11.7% 14.4% 3.4% −0.3% −2.0%
Free-cash-flow margin 12.0% 9.5% 1.6% 3.4% 5.1% 4.5% 12.0% 5.8% 6.3% 10.0% 6.8% 11.8% 7.9% 5.7% 8.2% 4.0% 1.3% 2.7%
Cash flow
Cash from operations 150 156 88 133 145 114 229 131 154 240 213 332 282 274 350 251 134 190
Capital spending 16 32 62 73 50 34 34 37 44 49 73 97 92 129 107 115 91 97
Free cash flow 134 124 26 60 95 81 195 94 111 191 140 235 190 145 243 136 43 94
Stock-based pay 6 7 8 8 7 9 8 9 11 11 10 16 17 28 31 25 20 20
Free cash flow after stock pay 127 117 18 53 88 71 187 84 100 179 131 219 173 118 212 111 23 74
Balance sheet
Cash 207 230 246 311 439 320 267 342 325 322 678 682 1,068 646 488 183 299 185
Total debt 0 487 303 337 355 355 266 412 416 341 813 845 1,334 1,219 1,282 2,094 1,869 1,825
Net debt (negative = net cash) −207 256 57 27 −84 36 −1 69 91 19 135 163 266 574 793 1,911 1,570 1,640
Diluted shares 165m 166m 167m 167m 169m 170m 169m 162m 159m 157m 157m 155m 153m 149m 147m 150m 152m 152m
Returned to shareholders
Dividends — — — — — — — 26 25 25 25 25 24 30 29 30 23 23
Buybacks — — — — — — 90 160 152 — 142 123 153 263 152 0 10 —
Total returned — — — — — — 90 186 178 25 167 148 178 293 182 30 33 23

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 6 checks passed · June 30, 2026
What it owns · $6.1bn
Short-term assets $2.2bnLonger-term assets $3.8bn
What it owes, and who funded it · $3.6bn
Short-term liabilities $1.2bnShareholders' equity $2.4bn
  • Short-term assets cover short-term liabilities $2.2bn of assets due within a year against $1.2bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
  • More cash than debt $185m of cash against $1.8bn of debt.
  • Debt below 40% of shareholders' equity Debt is 76% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 114% to 76% over five years.
  • A year's operating cash flow covers at least 20% of debt $190m of operating cash flow against $1.8bn of debt.
  • Operating profit covers interest at least five times over Operating income of −$31m against $62m of interest.

From Bruker Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q1 TTM
Buybacks (TTM)
$0
Dividends (TTM)
$22.6M
Returned to shareholders
44%
of free cash flow
Buybacks, last 3 fiscal years
$162M
Total shareholder yield
0.3%
dividends 0.3% + buybacks 0.0% of market value
R&D spending
11.2%
of revenue
Sales & admin spending
27.7%
of revenue
Days sales outstanding
57 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated BRKR CRL MTD MEDP ILMN FTRE Median
Revenue, last 12 months $3.5bn $4.0bn $4.1bn $2.8bn $4.5bn $2.7bn $229m
Revenue growth, last 12 months 1.6% −0.7% 6.9% 20.4% 5.8% −3.4% 6.9%
Revenue growth, 3-year average 8.8% −1.5% 1.5% 16.8% 0.5% 0.4% 2.9%
Revenue growth, latest quarter 5.2% −2.7% 4.5% 8.5% 4.2% −1.4% 8.5%
Gross margin 46.4% 36.7% 60.3% — 67.9% — 51.9%
Operating margin −0.9% 2.3% — 21.4% 21.2% 0.5% −14.3%
Operating margin, 3-year average 5.1% 6.4% — 20.9% 4.2% −12.5% −22.4%
Net margin −2.0% −6.0% 21.9% 18.2% 19.7% −2.6% −16.1%
Cash from operations / revenue 5.4% 14.6% 23.6% 25.5% 27.1% 7.6% 1.3%
Free-cash-flow margin 2.7% 9.3% 20.9% 23.5% 23.3% 6.3% −2.2%
Free-cash-flow margin, 3-year average 3.2% 11.9% 22.3% 26.0% 19.7% 4.7% 0.6%
Stock pay / revenue 0.6% 2.1% 0.6% 0.8% 5.9% 1.9% 4.4%
Change in share count −2.0% −3.9% −3.0% −5.1% −2.1% 1.3% 1.0%

Median of all 54 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

54 life sciences tools & services companies
Measure Company Peer median Rank
Revenue growth Growth 1.6% 6.9% 39 of 54
Change in growth rate Growth +1.3pp +0.4pp 20 of 54
Gross margin Profitability 46.4% 52.0% 29 of 45
Operating margin Profitability -0.9% -14.3% 19 of 52
Net margin Profitability -2.0% -12.2% 20 of 54
Free-cash-flow margin Cash generation 2.7% -1.3% 22 of 54
Stock pay as % of revenue Cash generation 0.6% 4.4% 2 of 53
Long-term debt as % of assets Balance sheet 30.0% 26.3% 22 of 35
Days sales outstanding Balance sheet 57 days 62 days 20 of 48

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Bsi Calid $1.2B 35.2% ▲ 10.7%
Bsi Nano $1.1B 31.6% ▼ 1.3%
Bsi Biospin $879M 25.6% ▼ 3.0%
Energy and Supercon Technologies $263M 7.7% ▼ 2.1%
Products and services
Line of business Revenue Share YoY
Products $2.8B 80.5% ▲ 0.3%
Other $670M 19.5% ▲ 10.4%
Geography
Region Revenue Share YoY
Europe Excluding Germany $950M 27.7% ▲ 8.8%
United States $891M 25.9% ▼ 5.0%
Asia Pacific Excluding China $553M 16.1% ▲ 6.6%
China $476M 13.8% ▲ 1.0%
Germany $297M 8.6% ▼ 4.4%
Other Country $270M 7.8% ▲ 5.9%

From Bruker Corp's 10-K filed February 27, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$8.5B
Institutions reporting
410
Shares held vs prior quarter
▲ 3.3%
Positions opened / closed
109 / 40

Top buyers and sellers, Q2 2026: 238 institutions bought and 162 sold ; the biggest buyer was FMR LLC (+4.1M shares) and the biggest seller Millennium Management LLC (−1.5M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
FMR LLC $1.2B 20.2M 14.3% ▲ 25.7%
Orbis Allan Gray Ltd $1.1B 17.9M 12.7% 0.0%
Blackrock, Inc. $686M 11.4M 8.1% ▲ 2.0%
Pallas Capital Advisors LLC $571M 9.5M 6.7% 0.0%
Vanguard Portfolio Management LLC $294M 4.9M 3.5% ▲ 0.7%
Vanguard Capital Management LLC $292M 4.9M 3.4% ▲ 0.9%
Sculptor Capital LP $278M 4.6M 3.3% ▲ 41.4%
State Street Corp $242M 4.0M 2.8% ▲ 2.8%
Franklin Resources Inc $194M 3.2M 2.3% ▲ 10.6%
Sachem Head Capital Management LP $175M 2.9M 2.1% New
Edmond De Rothschild Holding S.A. $170M 2.8M 2.0% ▼ 15.9%
Dimensional Fund Advisors LP $157M 2.6M 1.8% ▲ 11.5%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Bruker Corp's complete shareholder register. Values are as reported by the filers ; 3 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $3.6M 16 trades by 4 insiders · 81% under pre-set plans
Net ▼ $3.6M net selling
Insider Date Trade Shares Price Value
Munch Mark EXEC VP&PRES BRUKER NANO INC. September 15, 2026 Sell pre-set plan 2,000 $52.87 $105,740
Pusch Wolfgang President BMID Group August 17, 2026 Sell 3,473 $56.90 $197,614
Munch Mark EXEC VP&PRES BRUKER NANO INC. August 14, 2026 Sell pre-set plan 2,000 $57.60 $115,200
Munch Mark EXEC VP&PRES BRUKER NANO INC. July 15, 2026 Sell pre-set plan 2,000 $60.25 $120,500
Munch Mark EXEC VP&PRES BRUKER NANO INC. June 15, 2026 Sell pre-set plan 2,000 $54.76 $109,520
Munch Mark EXEC VP&PRES BRUKER NANO INC. May 15, 2026 Sell pre-set plan 2,000 $43.90 $87,800
Munch Mark EXEC VP&PRES BRUKER NANO INC. April 15, 2026 Sell pre-set plan 2,000 $39.90 $79,800
Munch Mark EXEC VP&PRES BRUKER NANO INC. March 13, 2026 Sell pre-set plan 2,000 $35.44 $70,880
Munch Mark EXEC VP&PRES BRUKER NANO INC. February 13, 2026 Sell pre-set plan 2,000 $36.94 $73,880
Munch Mark EXEC VP&PRES BRUKER NANO INC. January 15, 2026 Sell pre-set plan 2,000 $49.20 $98,400
Munch Mark EXEC VP&PRES BRUKER NANO INC. January 12, 2026 Sell pre-set plan 7,000 $55.00 $385,000
Munch Mark EXEC VP&PRES BRUKER NANO INC. January 5, 2026 Sell pre-set plan 15,337 $49.25 $755,347

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 3 trades and filings

No trades in Bruker Corp disclosed in the last 12 months; 3 earlier trades on record.

  • Bob Gibbs(R-OH 7):Sale (full), $1,001 - $15,000, traded November 27, 2020, filed December 24, 2020
  • Bob Gibbs(R-OH 7):Purchase, $1,001 - $15,000, traded November 14, 2019, filed November 26, 2019
  • Donna Shalala(FL):Sale (full), $1,001 - $15,000, traded June 24, 2019, filed April 27, 2020

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around October 15, 2026 estimated from the company's past filing pattern, not announced

  • August 4, 2026
  • May 6, 2026
  • February 12, 2026
  • January 12, 2026
  • November 3, 2025
  • August 4, 2025

Recent SEC filings

Data status

When each part of this page on Bruker Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Bruker Corp in brief

What does Bruker Corp do?
Bruker Corp is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
What is Bruker Corp's stock ticker?
Bruker Corp trades under the ticker BRKR on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Bruker Corp's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Bruker Corp reported revenue of $3.5B, 1.6% higher than a year earlier, according to its SEC filings.
What is Bruker Corp's free cash flow?
Bruker Corp's free-cash-flow margin is 2.7% of revenue over the trailing twelve months, ranking 22 of the 54 life sciences tools & services companies we cover.
Who are Bruker Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are FMR LLC, Orbis Allan Gray Ltd and Blackrock, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Bruker Corp's market cap?
On November 2, 2026, Bruker Corp's market capitalisation was about $8.5B and net debt of $1.6B. Market figures come from third-party market data and may be delayed.
Does Bruker Corp pay a dividend?
Yes: Bruker Corp paid $22.6M in dividends over the trailing twelve months, a dividend yield of 0.27%.
How much debt does Bruker Corp have?
Bruker Corp's debt-to-equity ratio is 75.6%, from its latest balance sheet (114.1% five years earlier). The financial health section below sets out its other solvency checks.
Who are Bruker Corp's competitors?
In our Life Sciences Tools & Services peer group, the companies closest to Bruker Corp are Charles River Laboratories, Mettler Toledo, Medpace Holdings, Inc., Illumina, Inc. and Fortrea Holdings Inc. The side-by-side comparison below sets their revenue, margins and growth against Bruker Corp's.
Are insiders buying or selling Bruker Corp stock?
Over the last 12 months, Bruker Corp's directors and officers reported 0 open-market purchases and 16 sales on Form 4. The insider trading page charts every trade.
When is Bruker Corp's next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Bruker Corp announces its own schedule.